Rekah Pharmaceutical Industry Ltd
TASE:REKA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 167
1 679
|
| Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gross Margin
Rekah Pharmaceutical Industry Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | IL |
| Market Cap | 162.5m ILS |
| Gross Margin |
23%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Gross Margin |
-3%
|
| Country | US |
| Market Cap | 710.5B USD |
| Gross Margin |
81%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Gross Margin |
56%
|
| Country | DK |
| Market Cap | 3.3T DKK |
| Gross Margin |
85%
|
| Country | US |
| Market Cap | 373.5B USD |
| Gross Margin |
69%
|
| Country | US |
| Market Cap | 251.1B USD |
| Gross Margin |
77%
|
| Country | CH |
| Market Cap | 202.7B CHF |
| Gross Margin |
73%
|
| Country | CH |
| Market Cap | 183.3B CHF |
| Gross Margin |
75%
|
| Country | UK |
| Market Cap | 162.4B GBP |
| Gross Margin |
82%
|
| Country | IE |
| Market Cap | 146B USD |
| Gross Margin |
68%
|
Rekah Pharmaceutical Industry Ltd
Glance View
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, import, marketing, sale, registration, and distribution of generic drugs, cosmetics, vitamins, and nutritional supplements. The firm operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The firm distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Rekah Pharmaceutical Industry Ltd's most recent financial statements, the company has Gross Margin of 23.3%.
You don't have any saved screeners yet
